285 related articles for article (PubMed ID: 37627318)
1. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis.
Driva TS; Schatz C; Haybaeck J
Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627318
[TBL] [Abstract][Full Text] [Related]
2. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
[TBL] [Abstract][Full Text] [Related]
3. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.
Samartzis EP; Labidi-Galy SI; Moschetta M; Uccello M; Kalaitzopoulos DR; Perez-Fidalgo JA; Boussios S
Ann Transl Med; 2020 Dec; 8(24):1712. PubMed ID: 33490224
[TBL] [Abstract][Full Text] [Related]
4. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
Wu R; Hu TC; Rehemtulla A; Fearon ER; Cho KR
Clin Cancer Res; 2011 Dec; 17(23):7359-72. PubMed ID: 21903772
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
10. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract][Full Text] [Related]
11. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
12. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
13. How Does Endometriosis Lead to Ovarian Cancer? The Molecular Mechanism of Endometriosis-Associated Ovarian Cancer Development.
Yachida N; Yoshihara K; Yamaguchi M; Suda K; Tamura R; Enomoto T
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809880
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway.
Cao Y; Ye Q; Zhuang M; Xie S; Zhong R; Cui J; Zhou J; Zhu Y; Zhang T; Cao L
PLoS One; 2017; 12(11):e0186520. PubMed ID: 29140979
[TBL] [Abstract][Full Text] [Related]
15. PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
Aziz AUR; Farid S; Qin K; Wang H; Liu B
Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29401696
[TBL] [Abstract][Full Text] [Related]
16. Endometriosis-Related Ovarian Cancer: Where Are We Now? A Narrative Review towards a Pragmatic Approach.
Centini G; Schettini G; Pieri E; Giorgi M; Lazzeri L; Martire FG; Mancini V; Raimondo D; Seracchioli R; Habib N; Fedele F; Zupi E
J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610698
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
[TBL] [Abstract][Full Text] [Related]
18. Effects of inhibiting the PI3K/Akt/mTOR signaling pathway on the pain of sciatic endometriosis in a rat model.
Liu Y; Qin X; Lu X; Jiang J
Can J Physiol Pharmacol; 2019 Oct; 97(10):963-970. PubMed ID: 31461309
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
20. PI3K-Akt-mTOR and MAPK signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: an update.
Makker A; Goel MM; Das V; Agarwal A
Gynecol Endocrinol; 2012 Mar; 28(3):175-81. PubMed ID: 21916800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
